Plant-Based  Proteins  with
Better Therapeutic Profiles

Protalix is dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with our ProCellEx® plant cell-based expression system

Learn more
Plant-Based  Proteins  with
Better Therapeutic Profiles Protalix is dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with our ProCellEx® plant cell-based expression system Learn more
  • Technology

    Learn more about our ProCellEx® plant cell-based protein expression system
  • FABRY

    Pegunigalsidase alfa is in Phase III for the treatment of Fabry disease
  • Cystic Fibrosis

    PRX-110 is in a Phase II clinical study for the treatment of cystic fibrosis
  • Inflammatory Diseases

    OPRX-106 oral treatment for inflammatory diseases is in a Phase II clinical study
  • Clinical Study Participation

    You may be eligible to enter our clinical study with our new enzyme replacement therapy for Fabry disease

    Learn More
  • Collaborate with Protalix

    We are actively seeking collaborations for our existing pipeline or in developing new therapeutic proteins

    Contact us